Han Minkyung, Sung Yoon-Kyoung, Cho Soo-Kyung, Kim Dam, Won Soyoung, Choi Chan-Bum, Bang So-Young, Cha Hoon-Suk, Choe Jung-Yoon, Chung Won Tae, Hong Seung-Jae, Jun Jae-Bum, Jung Young Ok, Kim Seong-Kyu, Kim Tae-Hwan, Koh Eunmi, Lee Hye-Soon, Lee Jisoo, Lee Joo-Hyun, Lee Shin-Seok, Nah Seong-Su, Shim Seung-Cheol, Yoo Dae-Hyun, Yoo Wan-Hee, Yoon Bo Young, Jee Sun Ha, Bae Sang-Cheol
From the Clinical Research Center for Rheumatoid Arthritis, Seoul; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul; Department of Rheumatology, Hanyang University Guri Hospital, Guri; Department of Rheumatology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul; Department of Rheumatology, Catholic University of Daegu School of Medicine, Daegu; Department of Rheumatology, Dong-A University Hospital, Busan; Department of Rheumatology, Kyung Hee University Hospital, Seoul; Department of Rheumatology, Hallym University Kangnam Sacred Heart Hospital, Seoul; Department of Rheumatology, Ewha Womans University Mokdong Hospital, Seoul; Department of Rheumatology, Inje University Ilsan Paik Hospital, Goyang; Department of Rheumatology, Chonnam National University Hospital, Gwangju; Department of Rheumatology, Soonchunhyang University Cheonan Hospital, Cheonan; Department of Rheumatology, Chungnam National University Hospital, Daejeon; Department of Rheumatology, Chonbuk National University Hospital, Jeonju; Department of Epidemiology and Health Promotion, Graduate School of Public Health Yonsei University, Seoul, Republic of Korea.M. Han, MPH, Clinical Research Center for Rheumatoid Arthritis; Y.K. Sung, MD, PhD, MPH, Clinical Research Center for Rheumatoid Arthritis, and Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; S.K. Cho, MD, PhD, Clinical Research Center for Rheumatoid Arthritis, and Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; D. Kim, MD, PhD, Clinical Research Center for Rheumatoid Arthritis, and Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; S. Won, MPH, PhD, Clinical Research Center for Rheumatoid Arthritis; C.B. Choi, MD, PhD, MPH, Clinical Research Center for Rheumatoid Arthritis, and Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; S.Y. Bang, MD, PhD, Department of Rheum
J Rheumatol. 2015 Nov;42(11):2075-81. doi: 10.3899/jrheum.141447. Epub 2015 Sep 1.
Rheumatoid arthritis (RA) is a chronic autoimmune disease that is often painful and debilitating. Patients with RA are increasingly receiving complementary and alternative medicine (CAM). We aimed to identify the patient characteristics and disease-specific factors associated with Korean patients with RA who decide to start treatment with CAM.
Among the total 5371 patients with RA in the KORean Observational study Network for Arthritis (KORONA), 2175 patients who had no experience with CAM were included in our study. In our study, we assessed the frequency of new incident CAM use, its patterns, and the predictive factors of new CAM use.
Of the 2175 patients, 229 patients (10.5%) newly started receiving CAM within a year of enrolling in the cohort. Of those who started treatment with CAM, 17.0% received only herbal medicine, 54.6% only acupuncture treatments (7.0% used a combination of both), and 21.4% "Other" (e.g., physical therapy and placental extract injections). Women (OR 1.89, 95% CI 1.13-3.14) and patients with depression (OR 3.52, 95% CI 1.65-7.50) were significantly more likely to be treated with CAM. Regarding household types, patients who lived in an extended family (OR 1.78, 95% CI 1.08-2.95) or as part of a couple (OR 1.55, 95% CI 1.07-2.24) were more likely to be treated with CAM than patients living in a nuclear family.
Our study found, within a year, an incidence rate of 10.5% for new CAM use among patients with no previous experience with CAM. Sex, depression, and household type were significantly associated with new CAM use.
类风湿性关节炎（RA）是一种慢性自身免疫性疾病，常伴有疼痛且使人虚弱。类风湿性关节炎患者越来越多地接受补充和替代医学（CAM）治疗。我们旨在确定决定开始使用补充和替代医学治疗的韩国类风湿性关节炎患者的特征及疾病相关因素。
在韩国关节炎观察研究网络（KORONA）的5371名类风湿性关节炎患者中，2175名无补充和替代医学使用经验的患者纳入我们的研究。在本研究中，我们评估了补充和替代医学新使用者的频率、使用模式以及补充和替代医学新使用的预测因素。
在2175名患者中，229名患者（10.5%）在入组队列后的一年内开始新接受补充和替代医学治疗。在开始接受补充和替代医学治疗的患者中，17.0%仅接受草药治疗，54.6%仅接受针灸治疗（7.0%同时使用两者），21.4%接受“其他”治疗（如物理治疗和胎盘提取物注射）。女性（比值比1.89，95%置信区间1.13 - 3.14）和抑郁症患者（比值比3.52，95%置信区间1.65 - 7.50）接受补充和替代医学治疗的可能性显著更高。关于家庭类型，与核心家庭的患者相比，生活在大家庭（比值比1.78，95%置信区间1.08 - 2.95）或夫妻家庭（比值比1.55，95%置信区间1.07 - 2.24）的患者接受补充和替代医学治疗的可能性更高。
我们的研究发现，在一年内，既往无补充和替代医学使用经验的患者中补充和替代医学新使用者的发生率为10.5%。性别、抑郁症和家庭类型与补充和替代医学新使用显著相关。
